SCHEMBL683656

SCHEMBL683656

Cc1cccc(N2CCN(Cn3cnc4c3c(=O)n(C)c(=O)n4C)CC2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.61
HTR6 P50406 1/20 0.61
MAPK1 P28482 1/20 0.59
L3MBTL1 Q9Y468 2/20 0.56
SMN1; SMN2 Q16637 4/20 0.51
ALDH1A1 P00352 3/20 0.51
LMNA P02545 2/20 0.51
MAPT P10636 2/20 0.51
TSHR P16473 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
USP2 O75604 1/20 0.51
HPGD P15428 1/20 0.51
ALOX15 P16050 1/20 0.51
KMT2A Q03164 1/20 0.51
HSD17B10 Q99714 1/20 0.51
TP53 P04637 1/20 0.49
RAB9A P51151 1/20 0.49
HTT P42858 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL683995 0.90 MAPK1 (0.72) HTR7HTR6MAPK1L3MBTL1SMN1; SMN2
SCHEMBL11150100 0.89 HTR7 (0.78) HTR7HTR6MAPK1L3MBTL1TSHR
SCHEMBL683655 0.88 HTR7 (0.77) HTR7HTR6MAPK1L3MBTL1SMN1; SMN2
SCHEMBL683994 0.88 RXFP1 (0.63) HTR7HTR6MAPK1L3MBTL1SMN1; SMN2
SCHEMBL682813 0.87 HTR7 (0.62) HTR7HTR6MAPK1L3MBTL1SMN1; SMN2
SCHEMBL684005 0.87 HTR7 (0.58) HTR7HTR6MAPK1L3MBTL1SMN1; SMN2
SCHEMBL683998 0.86 HTR7 (0.57) HTR7HTR6MAPK1L3MBTL1SMN1; SMN2
SCHEMBL683612 0.86 HTR7 (0.57) HTR7HTR6MAPK1L3MBTL1ALDH1A1
SCHEMBL684045 0.84 MAPT (0.50) HTR7HTR6MAPK1L3MBTL1SMN1; SMN2
SCHEMBL682814 0.84 HTR7 (0.56) HTR7HTR6MAPK1L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF HTR7 1398/4885HTR6 683/4885MAPK1 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.